Community pharmacist-led inhaler choice for improvement of lung function in COPD

A randomized controlled trial of community pharmacist-led inhaler choice for improvement of lung function in patient with COPD - CYCLE study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052218

Enrollment

Registered

2023-10-01

Start date

2023-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Patient -Watch the educational video with COPD and its medication. Community pharmacist 1) Measure peak inspiratory flow rate using Clement Clarke In-Check DIAL G16. 2) Counsell and choice perso

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients with newly diagnosed COPD indicating inhaler therapy

Exclusion criteria

Exclusion criteria: Stage IV (%FEV1<30%) Dementia Prognosis is predicted within one year Overlap with bronchial asthma Informed consent is not obtained

Design outcomes

Primary

Measure	Time frame
Change of FEV1 (Forced Expiratory Volume 1 second) from baseline to week 24	—

Secondary

Measure	Time frame
Forced Vital Capacity (FVC), Inspiratory Capacity (IC), COPD Assessment Test (CAT), Modified Medical Research Council (mMRC) Dyspnea Scale, EuroQol 5 dimensions (EQ-5D), Safety	—

Countries

Japan

Contacts

Public ContactEiji Shiwaku

Kyoto-Katsura Hospital Department of Pharmacy

shiwaku.eiji@katsura.com075-392-1609

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026